An update on the role of antihyperglycemic agents in diabetoporosis
Diabetes mellitus is a chronic disorder that progresses globally at an alarming rate. The impact of this disorder is severe as it deteriorates the quality of life due to its associated diseases such as kidney disease, cardiovascular disease, obesity, and neurological disorders and also disturbs bone...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-01-01
|
| Series: | Journal of Diabetology |
| Subjects: | |
| Online Access: | http://www.journalofdiabetology.org/article.asp?issn=2078-7685;year=2023;volume=14;issue=3;spage=117;epage=125;aulast=Sharma |
| _version_ | 1797645615303229440 |
|---|---|
| author | Nidhi Sharma Amit Kumar Nayak |
| author_facet | Nidhi Sharma Amit Kumar Nayak |
| author_sort | Nidhi Sharma |
| collection | DOAJ |
| description | Diabetes mellitus is a chronic disorder that progresses globally at an alarming rate. The impact of this disorder is severe as it deteriorates the quality of life due to its associated diseases such as kidney disease, cardiovascular disease, obesity, and neurological disorders and also disturbs bone metabolism. One of the major complications of diabetes is osteoporosis, which is frequently brought on by diabetes. Bone abnormalities and a higher risk of fractures are linked to both type type-1 diabetes and type-2 diabetes and hence diabetes is regarded as one of the risk factors for the occurrence of osteoporosis. In view of this, there is a need to assess the therapeutic role of hypoglycemic agents in the treatment of osteoporosis. Glucagon-like peptide-1 (GLP-1) agonist, a hypoglycemic class could be a novel and promising drug target in the management of osteoporosis due to its additional role in the bone remodeling process. It has also been reported that GLP-1 agonists can increase bone mineral density, improve bone quality, and prevent fractures in diabetic patients. This review highlights the recent findings by which antidiabetic medications are used in the treatment of diabetes-induced osteoporosis and also gives an insight into its pathophysiology and possible mechanisms that are involved in the treatment of diabetes-induced osteoporosis. However, more research is required to fully understand the therapeutic role and unique mechanism of GLP-1 agonists in the bone remodeling process. |
| first_indexed | 2024-03-11T14:50:27Z |
| format | Article |
| id | doaj.art-14aa11fc69924383978a93822ec73b41 |
| institution | Directory Open Access Journal |
| issn | 2078-7685 |
| language | English |
| last_indexed | 2024-03-11T14:50:27Z |
| publishDate | 2023-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Diabetology |
| spelling | doaj.art-14aa11fc69924383978a93822ec73b412023-10-30T09:41:16ZengWolters Kluwer Medknow PublicationsJournal of Diabetology2078-76852023-01-0114311712510.4103/jod.jod_35_23An update on the role of antihyperglycemic agents in diabetoporosisNidhi SharmaAmit Kumar NayakDiabetes mellitus is a chronic disorder that progresses globally at an alarming rate. The impact of this disorder is severe as it deteriorates the quality of life due to its associated diseases such as kidney disease, cardiovascular disease, obesity, and neurological disorders and also disturbs bone metabolism. One of the major complications of diabetes is osteoporosis, which is frequently brought on by diabetes. Bone abnormalities and a higher risk of fractures are linked to both type type-1 diabetes and type-2 diabetes and hence diabetes is regarded as one of the risk factors for the occurrence of osteoporosis. In view of this, there is a need to assess the therapeutic role of hypoglycemic agents in the treatment of osteoporosis. Glucagon-like peptide-1 (GLP-1) agonist, a hypoglycemic class could be a novel and promising drug target in the management of osteoporosis due to its additional role in the bone remodeling process. It has also been reported that GLP-1 agonists can increase bone mineral density, improve bone quality, and prevent fractures in diabetic patients. This review highlights the recent findings by which antidiabetic medications are used in the treatment of diabetes-induced osteoporosis and also gives an insight into its pathophysiology and possible mechanisms that are involved in the treatment of diabetes-induced osteoporosis. However, more research is required to fully understand the therapeutic role and unique mechanism of GLP-1 agonists in the bone remodeling process.http://www.journalofdiabetology.org/article.asp?issn=2078-7685;year=2023;volume=14;issue=3;spage=117;epage=125;aulast=Sharmaantidiabetic medicationdiabetes mellitusglp-1 agonistosteoporosis |
| spellingShingle | Nidhi Sharma Amit Kumar Nayak An update on the role of antihyperglycemic agents in diabetoporosis Journal of Diabetology antidiabetic medication diabetes mellitus glp-1 agonist osteoporosis |
| title | An update on the role of antihyperglycemic agents in diabetoporosis |
| title_full | An update on the role of antihyperglycemic agents in diabetoporosis |
| title_fullStr | An update on the role of antihyperglycemic agents in diabetoporosis |
| title_full_unstemmed | An update on the role of antihyperglycemic agents in diabetoporosis |
| title_short | An update on the role of antihyperglycemic agents in diabetoporosis |
| title_sort | update on the role of antihyperglycemic agents in diabetoporosis |
| topic | antidiabetic medication diabetes mellitus glp-1 agonist osteoporosis |
| url | http://www.journalofdiabetology.org/article.asp?issn=2078-7685;year=2023;volume=14;issue=3;spage=117;epage=125;aulast=Sharma |
| work_keys_str_mv | AT nidhisharma anupdateontheroleofantihyperglycemicagentsindiabetoporosis AT amitkumarnayak anupdateontheroleofantihyperglycemicagentsindiabetoporosis AT nidhisharma updateontheroleofantihyperglycemicagentsindiabetoporosis AT amitkumarnayak updateontheroleofantihyperglycemicagentsindiabetoporosis |